Despite the cardiovascular events associated with osimertinib, this drug has been associated with significant improvement in overall survival in EGFR-mutated NSCLC compared with older generation EGFR-TKIs (erlotinib and gefitinib).77 Here, EGFR is linked to non-small cell lung carcinoma.